Autopsy report · NCT04483687

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy

“Development program terminated”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Gilead Sciences

Sponsor type

Industry

Conditions

Ankylosing Spondylitis

Interventions

Filgotinib; Placebo to Match Filgotinib

Participants

0

Trials that died the same way

• GALLANT 22 Tesaglitazar vs. Placebo
  “The development program has been terminated” (92% match in meaning)
• Open Label Safety & Pharmacodynamic Study 24Wk w/DIO-902 Combo w/Metformin & Atorvastatin in T2DM Patients
  “Program terminated” (82% match in meaning)
• A Randomized Double Blind, Placebo Controlled Trial With AMG 108 in Patients With Type 2 Diabetes Mellitus
  “Program Development discontinued” (69% match in meaning)
• Clinical Study Evaluating Safety of a New Catheter for Urinary Intermittent Catheter in Healthy Volunteers
  “Product development project closed prematurely” (59% match in meaning)
• Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids (ASTEROID 4)
  “Due to a change in the development program, the study was closed prematurely.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.